Tata Consultancy Services (TCS), a leading IT services, consulting and business solutions firm, announced that it has been designated as a leader in Worldwide Life Science R&D Risk-Based Monitoring by global market intelligence firm, IDC, in the ''IDC MarketScape: Worldwide Life Science R&D Risk-Based Monitoring 2015 Vendor Assessment,''(doc HI255628, April 2015) report.

The report evaluated eight leading IT services vendors with significant RBM expertise, across a number of capability and strategy measures such as, offering roadmap, portfolio strategy, customer base, engagement capability, pricing model, investment, growth strategy, and more. IDC MarketScape's criteria selection, weightings and vendor scores, represent well-researched IDC judgements about the market and vendors through structured discussions, surveys and interviews with market leaders, participant buyers and end users.

TCS was recognised as a leader for its overall capability and extensive experience working with life sciences companies across all three sections of the industry: pharmaceutical, biotech and medical devices. The report further states that TCS brings a full spectrum of strong operational service capabilities to the clinical trial space, with particular strength in data management, analytics, systems integration, and RBM-specific operational processes.

Shares of the company gained Rs 42.3, or 1.66%, to settle at  Rs 2,594.05.  The total volume of shares traded  was  33,599 at the BSE (Friday).